Aceto Consolidates Acquisition of Six Manufacturers, Strengthening Its Unique Hybrid Model that Provides Major Supply Chain Benefits to Customers

Manufacturing Acquisitions Complement the Company’s Existing Strengths in Global Procurement and Distribution, Providing Unparalleled Supply Chain Flexibility and Dependability to Biopharmaceutical and Other Demanding Specialty Customers

GMP Manufacturing Footprint Now Extended to North America, Europe and India

Enhanced Capabilities Throughout the R&D and Drug Development Process

Increased GMP Manufacturing, Packaging and Ingredients Offerings

Strengthened Focus on Growth Markets in Biopharmaceutical, Vaccine, Nutraceutical and Cosmetic Segments

PORT WASHINGTON, N.Y.–(BUSINESS WIRE)–#ACBioBuffer–Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, today reported it has consolidated and integrated its six manufacturing-related acquisitions to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including pharmaceuticals, biopharmaceuticals, vaccines, nutraceuticals, agriculture, cosmetics and specialty chemicals. These developments are especially timely as the Covid-19 pandemic continues to show the fragility of global supply chains, requiring companies to rethink their current strategies and focus on achieving supply chain resilience and security.

“Over seven decades, Aceto built a leading position as a value-added global ingredients supplier sourcing thousands of specialty ingredients to customers demanding quality and reliability,” said Gilles Cottier, Chief Executive Officer of Aceto. “In the past few years, we have moved aggressively to complement and expand these capabilities by adding high quality manufacturing operations across key strategic global markets. Our core competencies and operations now span three continents, as well as the entire R&D and product development/manufacturing spectrum.”

Aceto’s operations in 10 countries handle more than 3,000 products, including reagents and process aids, intermediates, active pharmaceutical ingredients (APIs) and excipients. Its capabilities encompass R&D, production, quality assurance, supply chain management, global sourcing, Good Manufacturing Practices (GMP) grade manufacturing, and regulatory and quality compliance. The company’s expert procurement teams, which are strategically located in centers of excellence in key regions across Asia, Europe and North America, represent a major resource for Aceto’s customers. They are now strengthened by having access to Aceto’s own captive GMP manufacturing resources in addition to rigorously selected external suppliers.

Mr. Cottier added, “Our hybrid model and broad competencies provide agility and choice to our customers. This allows them to more rapidly develop and commercialize innovative products while assuring a diversified, flexible and dependable supply chain, whose critical importance has been so dramatically highlighted by the ongoing pandemic. In this regard, we are especially proud of our industry-leading on-time in-full rate. We intend to continue to invest in advanced systems and additional targeted acquisitions to further integrate and augment our operations and provide ever greater capabilities and value to our diverse and growing customer base.”

Prior to the Covid-19 pandemic, Aceto had recognized the growing demand in the pharmaceutical and biopharmaceutical sectors for high-quality critical GMP excipients and raw materials, and as part of its growth strategy it expanded its manufacturing footprint by acquiring six companies in less than 18 months, increasing its global R&D and GMP manufacturing capabilities. The acquired companies include:

• A&C – a global GMP manufacturer of specialty excipients, buffers, process solutions and raw materials for the biopharmaceutical sector.
• A&C Bio Buffer– a leading GMP manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products and vaccines.
• Cascade Chemistry – a manufacturer of APIs, regulatory starting materials and advanced intermediates, enabling Aceto to provide customers enhanced support throughout the drug development process and greater access to expanded North American manufacturing.
• Finar – a leading manufacturer, supplier and distributor of pharmaceutical excipients, lab chemicals, aquaculture inputs and food grade additives.
• Islechem – a specialty chemical manufacturing organization that also provides contract research and development, analytical services and technical support services.
• Syntor Fine Chemicals – a fine chemical manufacturer offering process development and R&D services.

About Aceto

Aceto is a leading global manufacturer and supplier of differentiated specialty ingredients to life sciences and advanced technology end markets. With business operations in 10 countries, Aceto manufactures and supplies over 3,000 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural and specialty chemical industries. In just two years Aceto has made six acquisitions of firms with expanded manufacturing, R&D and portfolio offerings, transforming the company into a worldwide supplier of critical raw materials with a robust manufacturing footprint. Aceto’s global operations, including a significant presence on the ground in China, India, Europe and North America, enable the company’s deep worldwide sourcing and regulatory capabilities. Aceto is well positioned to innovate new solutions, ensure quality and customize products to meet customers’ specific needs. Its expanded capabilities and decades of global sourcing expertise are especially valuable now that supply chain management is a critical strategic issue for companies worldwide. For more information visit aceto.com.

Contacts

Media:
Debra Harrsch

Brandwidth Solutions

[email protected]
(215) 997-8575